Exploration of key clinical trial data and real-world evidence on dupilumab in asthma and COPD presented at the ERS and CHEST ...

Once limited to nonspecific anti-inflammatory therapies, expanding treatment options for atopic dermatitis are allowing therapy to be individualized.

A multicentre clinical trial led by a researcher from the University of Sherbrooke will test a new therapeutic approach to moderate asthma. The study will include 150 patients, including 50 in Quebec, ...

Exdensur is now the first twice-yearly add-on maintenance therapy approved for use in severe eosinophilic asthma.

Patients with chronic spontaneous urticaria (CSU) often experience impaired QOL, especially when antihistamines, the standard ...

Eli Lilly and Co. disclosed positive top-line data from the phase III Attain-Maintain trial with orforglipron, a once-daily oral small-molecule GLP-1 receptor agonist. The compound was tested for ...

JAK inhibitor treatment is not associated with stunted growth in children with common inflammatory diseases, according to a ...

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is initiating a Phase 2 study ...